

Tchaikapharma High Quality Medicines Inc.
Consolidated Statement of financial position
as of 30 June 2026

	30.06.2026	31.12.2025
	<i>EUR'000</i>	<i>EUR'000</i>
Non-current assets		
Property, plant and equipment	17 249	17 889
Intangible Assets and Goodwill	1 953	1 844
Trade receivables	2 603	2 603
Non-current assets	21 805	22 336
Inventories	9 145	9 165
Trade and other receivables	41 951	40 465
Cash and cash equivalents	86	607
Current Assets	51 182	50 237
Assets	72 987	72 573
Issued capital	49 033	49 033
Statutory reserve	7 525	7 525
Retained earnings	5 466	3 071
Equity	62 024	59 629
<i>Equity Attributable to owners of the parent company</i>	<i>62 024</i>	<i>59 629</i>
<i>Non-controlling interest in equity</i>	<i>-</i>	<i>-</i>
Long term borrowings	573	789
Deferred tax liabilities	637	637
Non-current provisions for employee benefits	182	182
Non-current liabilities	1 392	1 608
Trade and other payables	5 072	5 590
Short term borrowings	4 443	5 228
Current tax liabilities	56	518
Current liabilities	9 571	11 336
Liabilities	10 963	12 944
Equity and liabilities	72 987	72 573


Date of preparation: 27.08.2026

Executive director:



Biser Georgiev

Prepared by:



Tsvetelina Pandeva

Tchaikapharma High Quality Medicines Inc.
Consolidated statement of comprehensive income
as of 30 June 2026

	30.06.2026	30.06.2025
	EUR'000	EUR'000
Revenue	19 141	16 389
Other income	1	1
Total income	19 142	16 390
Carrying amount of goods sold	(970)	(939)
Changes in inventories of finished products and work in progress	684	(24)
Materials and services	(12 261)	(9 122)
Personnel expenses	(2 895)	(2 688)
Depreciation / amortisation expenses	(758)	(708)
Other expenses	(237)	(176)
Finance income	6	30
Finance costs	(136)	(148)
Total expenses	(16 567)	(13 775)
Profit Loss before tax	2 575	2 615
Current tax expense income	(180)	(169)
Profit Loss	2 395	2 446
<i>Profit Loss attributable to owners of the parent company</i>	<i>2 395</i>	<i>2 446</i>
<i>Profit Loss attributable to non-controlling interests</i>	<i>-</i>	<i>-</i>
Other comprehensive income		
<i>Profit Loss attributable to owners of the parent company</i>		
<i>Profit Loss attributable to non-controlling interests</i>		
Comprehensive income	2 395	2 446
<i>Profit Loss attributable to owners of the parent company</i>	<i>2 395</i>	<i>2 446</i>
<i>Profit Loss attributable to non-controlling interests</i>	<i>-</i>	<i>-</i>
Earnings per share / in EUR per 1 share /	0.02	0.03

Date of preparation: 27.08.2026

Executive director:



Biser Georgiev

Prepared by:



Tsvetelina Pandeva

Tchaikapharma High Quality Medicines Inc.
Consolidated Cash flow statement
as of 30 June 2026

	30.06.2026	30.06.2025
	EUR'000	EUR'000
Cash flows from operating activities		
Receipts from sales of goods and rendering of services	12 535	11 246
Payments to suppliers for goods and services	(6 130)	(5 718)
Payments to and on behalf of employees	(2 881)	(2 701)
Income taxes paid classified as operating activities	(209)	(103)
Other cash payments from operating activities	(2 667)	(2 139)
Cash flows from used in operating activities	648	585
Cash flows from investing activities		
Purchase of other longterm assets classified as investing activities	(110)	(325)
Cash flows from used in investing activities	(110)	(325)
Cash flows from financial activities		
Dividends paid classified as financing activities	81	114
Proceeds from borrowings classified as financing activities	(830)	(113)
Repayments of borrowings classified as financing activities	(223)	(114)
Payments of lease liabilities classified as financing activities	(87)	(133)
Cash flows from used in financial activities	(1 059)	(246)
Increase/Decrease in cash and cash equivalents	(521)	13
Cash and cash equivalents	607	72
Cash and cash equivalents	86	85

Date of preparation: 27.08.2026

Executive director:

Biser Georgiev

Prepared by:

Tsvetelina Pandeveva

Tchaikapharma High Quality Medicines Inc.
Consolidated statement on changes in equity
as of 30 June 2026

	Issued capital <i>EUR'000</i>	Property plant and equipme nt revaluati on surplus <i>EUR'000</i>	Other reserves <i>EUR'000</i>	Retained earnings <i>EUR'000</i>	Equity abstract <i>EUR'000</i>	<i>Equity Attributab le to owners of the parent company EUR'000</i>	<i>Non- controllin g interest in equity EUR'000</i>
Balance as of 01.01.2025	46 937	2 208	4 488	2 324	55 957	55 957	-
Profit Loss				3 074	3 074	3 074	-
Other comprehensive income		598				598	-
Comprehensive income		598		3 074	3 672	3 672	-
Increase/Decrease through appropriation of retained earnings	2 096		231	(2 327)			
Total income expense	2 096		231	(2 327)			
Balance as of 31.12.2025	49 033	2 806	4 719	3 071	59 629	59 629	-
Balance as of 01.01.2026	49 033	2 806	4 719	3 071	59 629	59 629	-
Profit Loss				2 395	2 395	2 395	-
Other comprehensive income							-
Comprehensive income				2 395	2 395	2 395	-
Increase/Decrease through appropriation of retained earnings							-
Total income expense							-
Balance as of 30.06.2026	49 033	2 806	4 719	5 466	62 024	62 024	-

Date of preparation: 27.08.2026

Executive director:



Biser Georgiev

Prepared by:



Tsvetelina Pandeva